J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on GPCR stock, giving a Buy rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hardik Parikh has given his Buy rating due to a combination of factors that highlight the promising potential of Structure Therapeutics, Inc.’s aleniglipron. The recent Phase 2b trial results for the 120mg dose showed efficacy that met expectations, with significant weight loss and improved tolerability compared to previous trials. This positions the drug competitively in the market, especially as it moves towards Phase 3 trials where further improvements in adverse event rates are anticipated.
Additionally, the opportunity for oral obesity medications is seen as underappreciated, and aleniglipron’s status as a potential second-to-market oral GLP-1 agonist enhances its attractiveness for partnerships with larger pharmaceutical companies. The interest in obesity-related assets is strong, suggesting potential for further stock momentum. Moreover, Structure Therapeutics is also advancing in developing an oral small-molecule amylin, which could become a significant asset if future trials yield positive results.
In another report released today, Citi also reiterated a Buy rating on the stock with a $100.00 price target.